Lupin leader crosses fingers for fast resolution of Form 483

Lupin has big plans to build market share in the U.S., but those plans were stymied when the FDA cited a facility in Goa from which it expects to ship new products. The head of the Indian drugmaker is now saying that he thinks the facility is in good shape and that it will get an FDA signoff in the next couple of months.